Merck Signs Deals In Oncology And Alzheimer's Drug major will work with Pierre Fabre and Celera Diagnostics VIVIEN MARX
Merck and Pierre Fabre Médicament have signed a three-year contract to move monoclonal antibody F50035 into clinical development. Discovered by Pierre Fabre, the antibody targets a receptor that is overexpressed in tumor cells and may offer an immunotherapeutic approach to cancer. Merck will be responsible for manufacturing the antibody as well as related ones. It gets worldwide marketing rights, while Pierre Fabre retains exclusive rights to France and French-speaking countries. Meanwhile, Merck and Celera Diagnostics have begun to collaborate to find drug targets and biomarkers for Alzheimer’s disease. Merck has agreed to make milestone payments to Celera Diagnostics as well as pay royalties on sales generated from the joint effort. Celera Diagnostics is a joint venture between Celera Genomics and Applied Biosystems, both units of Applera Corp.
Chemical & Engineering News ISSN 0009-2347 Copyright © 2004